TPST
Tempest Therapeutics, Inc.
Key Financials
Net Income
$-26262000
↑ 37.2%
Revenue
$203000
N/A
EPS (Diluted)
$-6.33
↓ 322.0%
Total Assets
$16.9M
↓ 59.2%
Operating Income
$-26575000
↑ 36.8%
Total Liabilities
$10.3M
↓ 54.1%
Shareholders' Equity
$6.7M
↓ 65.1%
Cash & Equivalents
$7.7M
↓ 74.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 424B3 | 4/10/2026 | View on SEC |
| 424B3 | 4/10/2026 | View on SEC |
| EFFECT | 4/9/2026 | View on SEC |
| EFFECT | 4/3/2026 | View on SEC |
| D | 4/3/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| SCHEDULE 13D/A | 4/2/2026 | View on SEC |
| S-3 | 4/2/2026 | View on SEC |
| S-8 POS | 3/31/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TPST |
| Company Name | Tempest Therapeutics, Inc. |
| CIK | 1544227 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 415-798-8589 |